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Aims: Oral administration of probiotics has been known to improve inflammatory responses 
against infectious diseases. Here, we describe the inhibitory effect of oral intake of 
heat-killed Lactobacillus pentosus strain b240 (b240) on pneumococcal pneumonia in a 
murine experimental model.  
Method and Results: The mice treated with oral b240 for 21 days before Streptococcus 
pneumoniae infection exhibited prolonged survival time and less body weight loss, compared 
with saline-treated control mice. Mild pneumonia with significantly reduced secretion of 
inflammatory cytokines/chemokines according to related mitogen-activated protein kinase 
signalling molecules (phosphorylated c-Jun N-terminal kinase) was found in b240-treated 
mice, whereas severe pneumonia with hypercytokinemia was evident in control mice. 
Prominent reduction in the number of pneumococci and elevated expression of Toll-like 
receptor 2 and 4 in the lung tissues was concomitantly noted in b240-treated mice.  
Conclusions: These findings indicates that b240 has inhibitory effects on pneumococcal 
pneumonia induced by S. pneumoniae infection and improves inflammatory tissue responses, 
resulting in reduced damages to the respiratory tissues. 
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Significance and Impact of the Study: These results demonstrate that oral administration of 
b240 might protect host animals from S. pneumoniae infection by augmentation of innate 
immune response. 
 
Keywords: Lactobacillus pentosus strain b240, Probiotics, Streptococcus pneumoniae, 
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Pneumonia is the fourth leading cause of death in Japan (Anon., 2006). When deaths 
from pneumonia are analyzed by age, elderly patients (aged, >65 years) account for >90% of 
total deaths from pneumonia (Anon. 2006; Mandell et al. 2007; Seki et al. 2008; Anon. 2009). 
Approximately 25 per 100,000 persons are treated daily for pneumonia in Japan and 75 per 
100,000 persons die annually from it (Saito A, et al 2006, Anon 2006, Anon 2009) .  
Community-acquired pneumonia (CAP), an acute infection, occurs among 
individuals participating in ordinary social interactions. The bacterium most frequently 
isolated from patients with CAP is Streptococcus pneumoniae, followed by Haemophilus 
influenzae. The fatality rate associated with S. pneumoniae pneumonia is approximately 23%, 
despite the use of potent antibiotics and aggressive intensive care support (Anon. 2006; 
Mandell et al. 2007). Recently developed therapeutic techniques include effective vaccines, 
and control of overwhelming inflammatory reactions that are associated with tissue injury 
have been reported (Fisman DN, et al. 2006，Yanagihara et al. 2007). In fact, growing 
evidence suggest that the host immune response greatly contributes to the reduction of high 
mortality rate associated with this life-threatening infection (Seki et al. 2004a). 
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Probiotic lactic acid bacteria have been suggested to have effects, for example, 
anti-inflammatory properties (Gill et al. 2000; Ménard et al. 2004; Harata et al. 2010; Kawase 
et al. 2010). Probiotics are defined as live microorganisms that confer a health benefit on the 
host and are potential measures to regulate infection in the elderly (Fuller 1991; Gill and 
Guarner 2004). Administration of lactobacillus strain for 3 weeks has been shown to reduce 
the duration of winter infection, including viral (eg. cold, influenza) and bacterial (eg. 
pneumonia) infection, in free-living elderly (Turchet et al. 2003), and the World Health 
Organization (WHO) suggested that probiotics are helpful in normalizing nutrition status, 
especially in children (World Health Organization 2000). However, there is less information 
on the impact of probiotics on nutrition and immunological status of the elderly showing 
health-status changes due to infections such as pneumonia. 
While most previous studies used viable probiotic bacteria, we used heat-killed 
Lactobacillus plantarum strain b240 (b240) in the present study. We have found that Peyer’s 
patch (PP) cells stimulated with heat-killed b240 produce higher amounts of IgA than those 
stimulated with 150 other heat-killed lactic acid bacteria, and that IgA production in such PP 
cells is comparable to that in cells stimulated with viable b240 (Yamahira et al. 2006). In 
addition, the oral intake of heat-killed b240 for 3 weeks in clinical settings revealed 
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significant increase of secretory IgA (sIgA) levels in the saliva (Kishi et al. 2006). Moreover, 
oral intake of heat-killed b240 for 12 weeks is known to accelerate salivary IgA secretion 
even in the elderly (Kotani et al. 2010). This ability to efficiently induce sIgA in mucosal 
tissues, relevant to the adaptive immune response, prompted us to explore the ability of b240 
to exert in vivo protective effects against various infectious diseases. The effectiveness of oral 
administration of heat-killed b240 has been confirmed on mouse models of Salmonella and 
influenza infection (Ishikawa et al. 2010; Kobayashi et al. (in press)). Heat-killed lactic acid 
bacteria have an extended shelf life, are easier to store and transport, and exhibit less 
interaction with other components of food products during storage.  
In this study, the inhibitory effects of oral heat-killed b240 on pneumococcal pneumonia 
in mice infected with S. pneumoniae were investigated. 
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MATERIALS AND METHODS 
 
Bacteria Preparation and Infection 
Penicillin-sensitive S. pneumoniae ATCC 49619 strain was used. Bacteria were 
incubated in horse blood agar for 20 h at 37°C, scraped and suspended in Mueller-Hinton II 
Broth (Eiken Chemicals, Tokyo, Japan), mixed with Strepto Haemo supplement (Eiken 
Chemicals, Tokyo, Japan), and cultured for 6 h at 37°C at 250 rpm (BR-22FP; TAITEC Co., 
Ltd, Saitama, Japan). Bacteria were harvested by centrifugation for 10 min at 3000 × g. The 
harvested bacteria were suspended in saline at a concentration of 1 × 106 colony-forming 
units (CFU)/ml, as determined by the optical density method. 
The mice were challenged with or without pneumococci on the day following the 
end of b240 treatment. S. pneumoniae infection was induced by intranasal inoculation of 0.05 
ml of bacterial suspension (5 × 104 CFU/mouse) into mice under anesthesia (pentobarbital 
sodium, 70 mg kg-1 intraperitoneally (ip)). 
 
Laboratory Animals 
Five-week-old male CBA/J specific-pathogen-free mice (body weight, 16–20 g) 
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were purchased from Charles River, Japan. The details of the CBA/J mouse model of 
pneumococcal pneumonia has been previously described (Yanagihara et al. 2007). All mouse 
experiments were performed in accordance with the guidelines of the Laboratory Animal 
Center for Biomedical Research, Nagasaki University School of Medicine. 
 
Lactobacillus pentosus strain b240 and treatment regimes 
Lactobacillus pentosus strain b240 (ONRIC b0240: b240) was isolated from fermented 
tea leaves by Okada et al. (Okada et al. 1986). Strain b240 was initially identified as L. 
plantarum. Recently, Bringel et al. proposed re-classification of the L. plantarum group on 
the basis of the recA gene sequence (Bringel et al. 2005). On the basis of their proposal, we 
re-classified b240 as L. pentosus. 
Strain b240 was grown in MRS broth (Beckton Dickinson, Franklin Lakes, NJ, 
USA) at 33C for 24 h. The culture was washed twice with saline and suspended in deionized 
water, followed by autoclaving at 121C for 15 min. The heat-killed bacterial suspension was 
freeze-dried for storage. It was resuspended in saline before use. 
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 Mice received orally by gavage b240 at a rate of 500 mg kg-1 once in a day (total: 
12.5 mg kg-1 day-1) for 21 days before S. pneumoniae infection. Saline was administered 
orally as negative control.  
For survival study, mice were observed and evaluated for 14 days. For sample 
collection, mice were killed under anesthesia 2 days after infection, and the lungs were 
dissected under aseptic condition and suspended in saline. Lung tissue fixation was 
performed as described previously (Seki et al. 2004a). For tissue sectioning, lungs were 
excised and immersed in 10% phosphate buffered formalin. Paraffin embedding and tissue 
staining with hematoxylin and eosin (H&E) were performed using the standard methods. 
 
Bacteriological Examination 
Mice were killed under anesthesia 2 days after S. pneumoniae inoculation. For 
bacteriological examination, lungs were dissected under aseptic conditions and suspended in 
saline (1 ml). They were homogenized using a Shake Master NEO (Bio Medical Science, 
Tokyo, Japan). The lung homogenates were quantitatively inoculated onto blood agar plates 
by serial dilution, followed by incubation for 20 h. The lowest detectable bacterial level was 
50 CFU ml-1. 
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Enzyme-linked immunosorbent assay 
Concentrations of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), 
keratinocyte-derived cytokine (KC), and macrophage inflammatory protein (MIP)-2 in 
aqueous lung extracts were assayed by enzyme-linked immunosorbent assay using mouse 
Quantikine Kits (R&D Systems, Inc., Minneapolis, MN, USA). The lung homogenates were 
centrifuged for 60 min at 2,000 × g at 4°C, and the supernatants were collected as aqueous 
lung extracts and used in the assay. 
 
Western blotting 
Proteins in the lung homogenates were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene 
difluoride membranes (Millipore, Bedford, MA). The membranes were blocked with 5% 
skimmed milk in Tris-buffered saline (TBS; pH 7.2–7.4) containing 0.05% Tris-buffered 
saline with Tween 20 (TBS-T) and incubated with goat antibody (Ab) directed against 
toll-like receptor 2 (TLR-2) (Santa Cruz, CA, USA; diluted 1:500), TLR-4 (Santa Cruz, CA, 
USA; diluted 1:8000), Total c-Jun N-terminal kinase (abcom, USA; diluted 1:8000), 
phosphorylated c-Jun N-terminal kinase (abcom, USA; diluted 1:8000) or rabbit Ab directed 
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against β-actin (Sigma-Aldrich; diluted 1: 8,000) for overnight at 4C. The membranes were 
then washed with TBS-T and incubated with horseradish peroxidase (HRP)-conjugated 
anti-goat IgG (Santa Cruz, CA, USA; diluted 1:2,000) or HRP-conjugated anti-rabbit IgG 
(Santa Cruz, CA, USA; diluted 1:8,000) for 1 h at room temperature. After 2 additional 
washes, the signals were developed using an enhanced chemiluminescence (ECL) plus 
western blot detection kit (Amersham, Arlington Heights, IL). 
 
Statistical Analysis 
All data were expressed as means±SD and compared between the saline and b240 
administration groups. Survival curves after S. pneumoniae infection were estimated by the 
Kaplan–Meier method, and their homogeneity was evaluated by the log-rank test. The body 
weight of mice infected with S. pneumoniae was analysed by repeated measures analysis of 
variance (ANOVA). Differences between groups were tested for significance using unpaired 
t-test. Values with P < 0.05 were considered statistically significant and analysed using the 
SAS software R 9.1 (SAS Institute Japan, Tokyo, Japan). 




Long-term survival rates and nutrition status 
In order to assess the effects of b240, long-term survival rate was analyzed in S. 
pneumoniae-infected mice that were treated with b240 or saline (Fig. 1). In the controls 
(saline-treated mice), the mice started to die around day 5 after infection, around 50% of mice 
died by day 9, and all mice died by day 14, which was the end of the observation period. In 
contrast, all mice treated with b240 survived the first 9 days after infection, and 30% of mice 
survived even on day 14 (saline vs. b240 treated; P = 0.0664). 
Although the difference of survival mice number was not significant between saline 
or b240-treatment, we next investigated the nutrition status assessed by body weight loss (Fig. 
2). The mice treated with b240 significantly maintained the starting body weight until day 5 
after infection. The average body weights of the mice in the b240 group remained higher than 
those of the mice in the control group throughout the observation period. Notably, the weight 
of the mice in the b240 group were statistically higher than those of the mice in the control 
group between day 2 and day 5 after S. pneumonia infection (saline vs. b240 treated; P <0.05, 
from Day 2 to Day 5).  
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Inhibitory effects of bacterial growth and reduction of pneumonia severity  
The number of S. pneumoniae in lung tissues showed a 10–100-fold decrease in 
b240-treated mice on day 2 after infection significantly (P = 0.032), compared with that in the 
saline-treated mice (Fig. 3). However, there were no statistically significant differences in 
bacterial numbers in the lungs between the 2 groups after day 4 of infection (data not shown).  
Pathological examination of the lungs of control mice showed severe pneumonia 
(Fig. 4A and E), whereas those of b240-treated mice exhibited only mild to moderate 
pneumonia 2 days after infection (Fig. 4B and F). These differences are confirmed in terms of 
pathological features such as airspaces filled with inflammatory cells (arrow) and epithelial 
hyperplasia (arrowhead) (Fig. 4A and E), whereas b240-treated mice showed only very mild 
bronchopneumonia 2 days after S. pneumoniae infection (Fig. 4B and F). Similar 
pathological differences were also observed on day 4, although the differences became 
relatively smaller compared with those observed on day 2 (data not shown).  
In mice treated with either b240 or saline, but without pneumococcus infection, we 
did not find inflammatory changes (b240 only; Fig. 4C and G, saline only: Fig.4D and H, 
respectively). 
 
Tanaka A, Seki M, et al., Page 14 
 14
Reduced induction of inflammatory cytokines in the lungs 
Diverse cytokines are known to play a pivotal role within the airways during the 
course of infectious diseases, and the deleterious activation of inflammatory cells, including 
neutrophils, macrophages, and T cells, is associated with tissue injury (Seki et al. 2004a; 
Yanagihara et al. 2007; Seki et al. 2010). In line with this notion, the amounts of 
inflammatory cytokines in the lung tissues were investigated. TNF-α is expressed early in 
animal models of pulmonary infection caused by S. pneumoniae. It is a main trigger in the 
production of IL-6 as one of the most important mediators of inflammation (Kosai et al. 
2008). KC, as vELR+ CXC chemokines, including growth-related genes (GRO-α; CXCL1) 
and MIP-2(CXCL2/3; GRO-β/γ) were identified in the lung preparations obtained from mice 
with pneumonia (Strieter et al. 2002). Accordingly, the levels of TNF-α, IL-6, MIP-2, and 
KC were analyzed in the lung tissue homogenates on day 2 after S. pneumoniae infection. 
Intrapulmonary levels of TNF-α, IL-6, MIP-2 cytokines or chemokines were elevated 
significantly in the lungs by S. pneumoniae infection, indicating the presence of aggravated 
pulmonary inflammation induced by the infection (Fig. 5A-C). The KC level tended to 
decrease by the oral uptake of b240 (Fig. 5D), but the difference from that of the control 
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group was not statistically significant at Day 2. In the mice without pneumococcal infection, 
no production of cytokines and chemokines were observed either saline-or b240 treated. 
The suppression of all of them was markedly evident on day 2 after the infection and 
became marginal thereafter at Day 4 and 7 (data not shown).  
 
Mitogen-activated protein (MAP) kinase signalling in b240 treated lungs 
We  next performed kinetics of another immune-related molecules, such as MAP kinase 
to investigate more detailed mechanisms of this probiotic effect. We found activation of p38 
in S. pneumoniae infected mice, compared with non-infected mice. However, neither saline 
or b240 treatment decreased its activation,  
In contrast, activation of JNK was suppressed significantly in the lungs of b240 treated mice 
although S. pneumoniae infection According to cytokines/chemokines expressions and 
pathological changes (Fig. 6).  
 
Expression of Toll-like receptors 
Furthermore, we analysed the expression level of TLR2, known as key pattern 
recognition-type receptor for S. pneumoniae on mucus membrane (Seki et al. 2004a; Akira 
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2006; Miyauchi et al. 2008). Innate immune systems have been suggested to play a critical 
protective role against pathogens on the mucus membrane in the airways (Gill et al. 2000; 
Gill and Guarner 2004;Racedo et al. 2006; Villena et al. 2008). Significant upregulation of 
TLR2 was observed 2 days after the infection in whole lung tissues of mice treated with oral 
b240 (Fig. 6). In addition, expression level of TLR4 was increased significantly in the lungs 
of mice treated with b240. These expression were not observed in the lungs of non-infected 
mice either saline or b240 treated. 




Oral intake of heat-killed Lactobacillus pentosus strain b240 did not show the 
prolongation of survival time, but led to significant reduction of body weight loss, as well as 
reduced bronchitis, in the present pneumococcal pneumonia model. There was a significant 
reduction in the secretion level of inflammatory cytokines in b240-treated mice in accordance 
with the alleviated pathological severity of pneumonia. We tried more 3 days administration 
of b240 after infection, but could not continue more prolonged oral administration because 
the mice became weaken after S. pneumoniae infection. In addition, survival and weight loss 
rates in above regimen were same as the regimen stopped after infection (data not shown).  
Effective pulmonary host defense against respiratory pathogens is believed to be 
mediated via innate and adaptive immune responses such as the stimulation of phagocytosis 
by alveolar macrophages and recruited neutrophils, IgA secretion, and upregulation of pattern 
recognition receptors, including TLR2 and 4 (Akira 2006). If pneumococci overcome these 
host defenses and gain entry into the bloodstream, systemic protection is afforded by 
anti-capsular antibodies (Lee et al. 2005). Such defenses are also produced by a 
spatiotemporally regulated inflammatory response coordinated by diverse cytokines (Seki et 
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al. 2004a; Akira 2006; Yanagihara et al. 2007).  
In our infection model, b240 induced faster clearance of the pathogen, which was 
reflected by the reduced number of pneumococci in the lung and reduced body weight loss in 
the treated group compared to that in the control group. Administration of b240 was able to 
induce a rapid and early increase in polymorphonuclear leukocyte (PMN) cells (data not 
shown). Although PMNs are a key component of the host defense response against invading 
pathogens, they have also been implicated as mediators of tissue injury (Seki et al. 2004a, 
2004b; Yanagihara et al. 2007; Seki et al. 2010). The regulation of inflammatory responses 
by anti-inflammatory cytokines prevents damage to the host. Lactobacillus has been 
suggested to participate in tissue protection against the deleterious effect of an ongoing 
inflammatory processes (Blum et al. 1999). Intrapulmonary levels of TNF-α, IL-6, and 
MIP-2 were elevated in the lung tissue by S. pneumoniae, indicating the presence of 
aggravated pulmonary inflammation. The reduced induction of these cytokines by oral b240 
administration clearly indicates the beneficial effect of b240 to ameliorate the tissue injury 
caused by local inflammation. The histopathological examination of lung tissues showed that 
both the inflammatory response and tissue damage were significantly reduced in mice treated 
with b240. These results suggest that b240 treatment beneficially regulates the balance 
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between Th1 and Th2 cytokines, biased to a protective inflammatory response against 
infection. TNF-αcould also inhibit the onset of bacteremia by stimulating antibody 
production and neutrophil recruitment and by promoting the antimicrobial activity of 
phagocytic cells (Takashima et al. 1997). The suppression was markedly evident on day 2 
after the infection and became marginal thereafter.  
In order to evaluate the relationships between cytokines and the pathological 
changes, the related molecules, not only TLRs bu also MAPK were investigated in terms of 
activation in b240-treated lungs. The production of cytokines and chemokines in response to 
components of microbiological agents is stimulated by TLRs and mediated by MAPK 
signaling ( Xu et al. 2008). Activation of MAPK-related molecules, such as JNK, was 
observed. These data suggest that MAPK signalling cytokine secretion pathways may be 
involved in the lung damage noted in pneumococcal infected mice and b240 could suppress 
the inflammation via this pathway. However, we could find suppression of JNK, but not p38 
in this study. Kenzel S. et al. reported P38, but not JNK, is critical for phagocytosis of GBS 
by macrophages. RAW 264.7 cells (Kenzel et al 2006). Further investigation about these 
discrepancy will be needed. 
 The mucosal immune system is able to respond to invading pathogens in the 
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respiratory tract by producing pathogen-specific sIgA Ab (Lee et al. 2005;Racedo et al. 2006, 
Fukuyama et al. 2006., Tamura et al. 1990). Mice treated with L. casei for 2 days showed 
higher levels of anti-pneumococcal serum IgG and bronchoalveolar lavage (BAL) IgA than 
those in the control group (Racedo et al. 2006). In this study, we investigated the production 
of total IgA Ab in the nasal lavage fluid (NLF) that may cause non-specific reactions to 
streptococcal colonization, however, those in NLF of b240 group on day 2 was not 
significantly higher than that of the control group (data not shown). In this context, S. 
pneumoniae-specific sIgA level should be measured for precisely understanding the 
protective effect of b240 through pathogen-specific sIgA Ab in a future investigation. 
 TLRs play a key role in the innate immune recognition of multiple bacterial 
pathogens, including S. pneumoniae (Seki et al. 2004a;Akira 2006; Miyauchi et al. 2008). 
Among them, TLR2 is usually involved in the recognition of gram-positive bacteria, and its 
upregulation was induced by the administration of L. paracasei F19 (Akira 2006; Cammarota 
et al. 2009). We observed significant expression of TLR2 protein in the b240-treated mice, 
indicating the augmentation of innate immune response by b240. In addition, TLR4 was also 
upregulated in b240-treated mice. These results suggested b240 could induce novel innate 
immune reactions and might be benefitical for protection against bacteria invasion. The 
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detailed mechanism underlying the upregulated expression of TLR2 and 4 by b240 needs to 
be urgently with further. 
Collectively, we found not only TLR2, but also TLR4 were significantly induced in 
the mice lungs treated by b240 oral-intake. Furthermore, we examined kinetics of another 
immune-related molecules, such as MAP kinases and found significant down-regulated of 
these molecules’ activation according to decrease of inflammatory cytokines/chemokines 
in b240-treated mice. These interesting results believed to explain anti-inflammatory and 
host defense mechanisms of b240-treated pneumococcal pneumonia by TLRs activation. 
In addition, we focused on probiotics L. pentosus strain b240 in this study because 
we previously found this strain showed much higher induction of IgA in vitro 
experiments (Yamahira S. et al. 2006). In brief, we extracted peyer’s patch cells from 
small intestine of mice, and soluble IgA in supernatant of the cell culture was measured 
by ELISA. L. pentosus strain b240 was the most effective strain for IgA production 
among many different bacterial strains. These results were also believed to explain the 
mechanisms how the Lactobacilli decrease the severity of pneumonia in vivo. We could 
not investigate another strain unfortunately in this study, but further examination to detect 
the potential of other probiotic strain in vivo will be needed. 
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In conclusion, the results obtained in this study may lead to new insights concerning 
the use of b240 as an oral adjuvant or as an oral vaccine vector for a wide range of infectious 
lung diseases. Further detailed studies are necessary to elucidate the molecular mechanisms 
underlying the effects of b240 in pneumonia in animal models and humans. 
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Fig. 1 Survival rates of mice treated with saline or b240 infected with S. pneumoniae. Mice 
were treated with saline or b240 from 21 days before S. pneumoniae infection. Each group 
comprised 9 mice (● and normal line: saline-treated mice, and  and dotted line: 
b240-treated mice).  




Fig. 2 The body weight of S. pneumoniae-infected mice treated with saline or b240. Mice 
were treated with saline or b240 from 21 days before S. pneumoniae infection. Each group 
comprised 9 mice (● and normal line: saline-treated mice, and  and dotted line: 
b240-treated mice). Body weight loss was significantly reduced in b240-treated mice 
compared with that in saline-treated mice, from day 2 to day 5 after infection (P = 0.0133, 
0.0256, respectively). Statistically significant differences are indicated as follows: * P < 0.05 
compared to saline and b240 groups at day 2, 3, and 4. 




Fig. 3 Bacterial numbers in the lungs of S. pneumoniae-infected mice treated with saline or 
b240. Bacterial numbers were significantly reduced in b240-treated mice compared with that 
in the saline-treated mice at day 2. Each group comprised 6 mice. * indicates a statistically 
significant difference (P =0.032) compared to saline and b240 groups. 
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Fig. 4 Pathological analysis of the lungs of S. pneumonia-infected or non-infected mice 
treated with saline or b240. Lungs were collected 2 days after with or without S. pneumoniae 
infection and representative photos are shown. A–H) eosin-stained tissue sections at 
magnifications of A) -D): ×40, and E) - H): ×200. A) and E): saline-treated (control) mice 
with pneumococcal infection, B) and F): b240-treated mice with pneumococcal infection, C) 
and G): b240-treated without pneumococcal infection, and D) and H): saline-treated without 
pneumococcal infection, respectively. 
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Fig. 5 Concentrations of inflammatory cytokines on day 2 in the lungs of mice treated with 
saline or b240. These mice were infected or non-infected with S. pneumoniae. (A) TNF-α, 
(B) IL-6, (C) MIP-2, and KC (D), respectively. Each group comprised 4–7 mice. (day 2 and 4, 
n = 4; day 7, n = 7). * indicates statistically significant difference (P < 0.05) compared to all 
other groups. 
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Fig. 6 Activation of p38 and c-Jun N-terminal kinase (JNK), signalling factors in the 
Toll-like receptor-mediated cytokine production pathway, in the whole lungs of S. 
pneumoniae-infected or non-infected mice treated with saline or b240 on day 2. Levels of 
activation were analysed by Western blotting, using antibodies directed against each 
phosphorylated (activated) form and intact form The experiment was repeated three times; 
representative results are shown. 
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Fig. 7 Increased expression of TLR2 and TLR4 in the whole lungs of S. pneumoniae-infected 
or non-infected mice treated with saline or b240. Lungs were collected 2 days after S. 
pneumoniae infection, and representative photos are shown. 
 
